FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. PMID 35403447 · Thyroid · 2022-May The record is an original, formal result report of a randomized, double-blind, drug-intervention oncology trial with a primary time-to-event endpoint (PFS). However, it is explicitly a Phase 4 trial, which does not meet the required Phase III/IIIb or Phase II/III criterion. The phase cannot be inferred or upgraded. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Optimizing treatment for non muscle-invasive bladder cancer with an app. PMID 35307306 · Actas Urol Esp (Engl Ed) · 2022-May Record lacks explicit Phase III/IIIb or Phase II/III classification; primary outcomes are recurrence/progression rates and risk ratios, not time-to-event endpoints; intervention is an app and intravesical BCG (immunologic adjuvant), not a systemic drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A multilevel, low literacy dual language intervention to promote colorectal cancer screening in community clinics in Florida: A randomized controlled trial. PMID 35305995 · Prev Med · 2022-May The study is a randomized controlled trial in oncology (colorectal cancer screening) with human participants and reports original results. However, it is excluded because: 1) The intervention is a multilevel educational/coaching program, not a drug-containing intervention. 2) The primary outcome is binary (completed FIT within 1 year), not a time-to-event efficacy endpoint like OS, PFS, DFS, or HR from Kaplan-Meier analysis. 3) The trial phase is not specified as Phase III/IIIb or Phase II/III; it appears to be a pragmatic/implementation trial. Therefore, it does not meet the eligibility criteria for the cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial. PMID 35105476 · Eur Urol · 2022-May Excluded because it is a non-drug-only trial (radiotherapy dose modification) and lacks an indicated time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. PMID 35279214 · Trials · 2022-Mar-12 The study meets all other eligibility criteria (oncology, human, randomized, drug intervention, original result, time-to-event endpoint) but the explicit phase (Phase III/IIIb or Phase II/III) is not established in the provided information. The publication types list 'Randomized Controlled Trial' but do not specify a phase. The abstract text does not mention the phase. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients. PMID 35451408 · Medicine (Baltimore) · 2022-Mar-11 The record is a protocol for a randomized trial in oncology with a drug intervention, but it is not an original result report and does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Plasmalyte-A Based del Nido Cardioplegia Versus Plain Ringer Based del Nido Cardioplegia: Double-Blind Randomized Trial. PMID 35238704 · World J Pediatr Congenit Heart Surg · 2022-Mar The study is a randomized controlled trial in pediatric cardiac surgery (Tetralogy of Fallot repair) comparing two cardioplegia solutions. It is not an oncology study, does not involve a systemic drug intervention for malignancy, and does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The primary outcome is a change in cardiac index (a continuous physiological measure), and secondary outcomes include clinical and biochemical markers, none of which are survival or time-to-event outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. PMID 35152272 · Prostate Cancer Prostatic Dis · 2022-Mar The study is a randomized exercise intervention trial in metastatic castration-resistant prostate cancer. It does not meet key eligibility criteria: (1) It is not a Phase III or definitive Phase II/III trial (phase not specified, likely Phase II exploratory); (2) The intervention is exercise, not a drug; (3) The reported outcomes are biomarker (myokine) levels and in-vitro cell growth, not time-to-event clinical efficacy endpoints (OS, PFS, etc.) or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial. PMID 34904225 · Br J Haematol · 2022-Mar The record is a long-term follow-up report of a randomized trial in human oncology with a drug intervention and time-to-event efficacy endpoints. However, the formal trial phase (e.g., Phase III, Phase II/III) is not explicitly stated in the provided metadata or abstract, preventing confirmation of the 'phase3_or_definitive' criterion. The is_eligible flag is set to null because this key criterion cannot be established from the available information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. PMID 34657128 · Leukemia · 2022-Mar The record is a Phase III oncology study with a drug intervention and reports original results. However, it is not eligible because the abstract does not establish a primary or key secondary time-to-event efficacy endpoint as required. The analysis is prognostic (impact of genetic abnormalities on survival) but does not explicitly state the endpoint type (e.g., OS, PFS) or present time-to-event statistics (HR, Kaplan-Meier). Randomization status is not confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Expectations, experiences and preferences of patients and physicians in the informed consent process for clinical trials in oncology. PMID 34618238 · Support Care Cancer · 2022-Mar The record is a qualitative study on informed consent in oncology trials, not an original report of trial efficacy results. It does not specify a drug intervention or report any time-to-event outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer. PMID 32822222 · Cancer Biother Radiopharm · 2022-Mar The record meets most inclusion criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result) but does not explicitly establish that it is a Phase III/IIIb or Phase II/III trial. The phase is a required criterion for eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The Effects of Theory-Based Educational Intervention and WhatsApp Follow-up on Papanicolaou Smear Uptake Among Postnatal Women in Malaysia: Randomized Controlled Trial. PMID 35759319 · JMIR Mhealth Uhealth · 2022-Jun-27 The study is a randomized trial in oncology (cervical cancer screening), but it tests a non-drug, theory-based educational and WhatsApp intervention, and its primary endpoint is the proportion of Pap smear uptake (a binary/categorical outcome at a fixed time), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the core criteria of a drug-containing intervention with a time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. PMID 35385794 · Life Sci · 2022-Jun-15 The study is a randomized, placebo-controlled trial with a drug intervention (mebendazole) and reports time-to-event efficacy endpoints (PFS and OS). However, the abstract does not explicitly state the trial phase (e.g., Phase III or Phase II/III). While the methods describe a 'prospective, randomized double blind placebo-controlled study' and the title mentions 'drug repurposing,' it does not specify a definitive Phase III/IIIb or Phase II/III designation. The metadata (publication types, mesh) also does not confirm the phase. Therefore, the phase criterion cannot be established with certainty. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. PMID 35642485 · Haematologica · 2022-Jun-01 The record is a narrative review discussing the management of chemotherapy-induced thrombocytopenia. While it mentions Phase III randomized trials as needed, it does not report the results of any such trial. There is no time-to-event efficacy endpoint (OS, PFS, etc.) reported. Therefore, it fails the criteria for an original result report of a randomized trial with a time-to-event endpoint. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08). PMID 33055589 · Ann Surg · 2022-Jun-01 The record describes a Phase III randomized trial with a drug-containing intervention and time-to-event endpoints (OS, PFS) mentioned. However, the primary analysis reported is on surgical outcomes and complications, not the efficacy of the drug intervention. The abstract does not explicitly confirm randomization (though trial registration and design imply it), and the results focus on surgical technique comparisons and prognostic factors (lymph node ratio), not the Kaplan-Meier analysis or hazard ratios for the drug intervention. Therefore, while it is an oncology, human, Phase III, drug intervention trial with time-to-event endpoints, it does not meet the criterion of having a primary/key secondary time-to-event efficacy endpoint as the focus of the report, and randomization evidence is not explicit. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Not Available]. PMID 35671969 · Aktuelle Urol · 2022-Jun The record includes a Phase III clinical trial on human prostatic neoplasms, which is oncology and human. However, the abstract is missing, and there are no keywords or mesh terms indicating a time-to-event endpoint (e.g., OS, PFS, HR, Kaplan-Meier) or a drug-containing intervention. The publication type indicates Phase III but does not explicitly confirm randomization. Therefore, eligibility cannot be established due to insufficient information on key criteria (time-to-event, drug intervention, randomization). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol. PMID 35193775 · Eur Urol · 2022-Jun The record is a meta-analysis of Phase 3 trial results, which is an excluded report type. Without the abstract, it cannot be confirmed that this specific publication presents a primary result with a time-to-event endpoint for a single trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies. PMID 35080260 · Clin Exp Dermatol · 2022-Jun The study is a retrospective analysis comparing BRAF V600K vs. V600E melanoma patients using propensity-score matching, not a prospective Phase III randomized trial with a drug intervention and time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. PMID 34530470 · Thromb Haemost · 2022-Jun The record describes a protocol for a randomized trial in venous thromboembolism, not an oncology trial. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and is not a results report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. PMID 35902898 · BMC Pharmacol Toxicol · 2022-Jul-28 The trial is a randomized Phase III oncology study with a drug intervention (trastuzumab biosimilar vs. reference) and reports original results. However, the primary and key secondary efficacy endpoints (pathologic complete response, overall response rate, breast-conserving surgery) are not time-to-event endpoints (e.g., OS, PFS, DFS) and no Kaplan-Meier curves or hazard ratios for such endpoints are reported. Therefore, it does not meet the time-to-event efficacy endpoint criterion required for eligibility. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial. PMID 35708709 · JAMA Oncol · 2022-Jul-01 The record describes a randomized clinical trial with a drug-containing intervention (pegaspargase-based vs L-asparaginase-based chemotherapy), reports primary time-to-event efficacy endpoints (PFS, OS), and is an original result report. Phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata; however, the trial's size (87 randomized patients), multi-center design, comparison of standard-of-care regimens, and definitive primary endpoint (PFS) are highly indicative of a phase III trial, but the strict requirement for explicit phase evidence prevents a definitive 'true' rating for phase3_or_definitive. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. PMID 35576721 · Eur J Radiol · 2022-Jul The study is a randomized oncology trial on human breast cancer, but it does not involve a drug-containing intervention, does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, HR), and is not a Phase III/IIIb or definitive Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. PMID 35476316 · Br J Haematol · 2022-Jul The record reports on a secondary analysis of a Phase III randomized trial (JAKARTA) and a Phase II single-arm trial (JAKARTA2) evaluating a drug intervention (fedratinib) in myelofibrosis. However, the primary efficacy endpoint is categorical spleen/symptom response at 24 weeks, not a time-to-event endpoint (e.g., OS, PFS). No Kaplan-Meier curves, hazard ratios, or time-to-event data are mentioned. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for inclusion in the cohort. |
H
L
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. PMID 35341945 · J Clin Epidemiol · 2022-Jul This record describes a methodological study that analyzed the eligibility criteria of 40 published phase III breast cancer trials. It is not an original report of the results (e.g., efficacy, safety) from a single randomized trial with a drug intervention and a time-to-event endpoint. The abstract does not present any clinical outcome data (OS, PFS, etc.), Kaplan-Meier curves, or hazard ratios for a specific trial. Therefore, it does not meet the core eligibility criteria for the cohort. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. PMID 34785763 · Cancer Gene Ther · 2022-Jul The record describes a post-hoc subgroup analysis of a randomized trial, which is excluded per criteria. Additionally, the trial phase is not explicitly stated in the provided metadata or abstract, preventing confirmation of a Phase III/IIIb or Phase II/III requirement. Therefore, eligibility cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| 18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. PMID 34675112 · J Nucl Med · 2022-Jul The record describes a randomized trial of an oncologic drug regimen in human diffuse large B-cell lymphoma with a PFS endpoint and original results. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (publication types do not include 'Phase III' and abstract does not specify phase). Furthermore, the primary focus of the abstract is on biomarker/predictive analysis rather than the primary efficacy comparison of the drug intervention. Therefore, eligibility is uncertain; metadata cannot definitively establish all required criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment. PMID 35073519 · Aging (Albany NY) · 2022-Jan-24 The record describes a retrospective study developing a predictive radiomics model for PD-1 inhibitor efficacy in advanced gastric cancer. While it involves human cancer patients, a drug intervention, and reports a PFS endpoint, it is not a Phase III/IIIb or Phase II/III randomized trial reporting primary results of a drug intervention. The randomization mentioned is for splitting data into training/validation sets for the model, not for comparing treatment arms in a clinical trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Evaluating biomarkers for treatment selection from reproducibility studies. PMID 32424421 · Biostatistics · 2022-Jan-13 The record is a methodological article proposing a statistical approach for biomarker evaluation, applied to a cancer study. It does not meet the criteria for an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. PMID 34643947 · Cancer · 2022-Jan-01 The record reports a secondary subgroup analysis from a randomized trial, not the primary result report. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. PMID 35027760 · Nat Med · 2022-Jan The record is a publisher correction (erratum) to a primary trial report. While the original trial appears to be a randomized phase 3 oncology study with a drug intervention, this specific document is not the original formal result report. It is a correction notice, which is excluded. The original trial's time-to-event endpoints cannot be assessed from this record alone. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Nonparametric inference in the accelerated failure time model using restricted means. PMID 35018550 · Lifetime Data Anal · 2022-Jan This is a statistical methods paper proposing a new estimator for survival analysis, using an example from a randomized clinical trial for illustration. It is not an original report of a randomized trial's efficacy results. The publication types list 'Randomized Controlled Trial', but the abstract describes it as a 'Journal Article' proposing methodology and an example. It does not present novel trial results, only illustrates the method. It lacks a clear drug-containing intervention arm vs. control design description in the abstract. The primary focus is on statistical inference, not reporting trial outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements? PMID 34798371 · Transl Oncol · 2022-Jan The abstract is a commentary on the design and control arm of the EMERALD trial, not an original report of trial results. It does not present any Kaplan-Meier curves, hazard ratios, or other primary time-to-event efficacy data for the drug intervention. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. PMID 34798037 · Lancet Gastroenterol Hepatol · 2022-Jan The study is a Phase III randomized trial for ulcerative colitis, which is not a human malignant neoplasm. The primary efficacy endpoint is remission at week 62, a non-time-to-event outcome. Therefore, it does not meet the eligibility criteria for an oncology Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. PMID 34797506 · Adv Ther · 2022-Jan This record is an indirect comparison (MAIC) of two separate Phase III trials, not an original report of a single randomized trial with direct results. Therefore, it is excluded as not being an original result of a randomized trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy. PMID 34779394 · Int J Clin Pharmacol Ther · 2022-Jan The record is an analysis of multiple existing studies, not an original result report of a single definitive randomized trial. Eligibility cannot be confirmed without explicit evidence that the analysis pertains to a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. PMID 34773086 · Nat Rev Clin Oncol · 2022-Jan The record has strong Phase III and time-to-event signals but lacks an abstract and explicit randomization evidence, making it impossible to confirm if this is an original result report of a randomized trial. Eligibility cannot be determined. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. PMID 34396513 · Br J Haematol · 2022-Jan The record describes a retrospective subgroup analysis focusing on histopathological growth patterns within the HD18 trial. While the underlying trial is randomized and reports time-to-event efficacy data, this specific publication is a secondary analysis of a biomarker/subgroup, not the primary report of the trial's main efficacy results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. PMID 34058953 · Expert Rev Pharmacoecon Outcomes Res · 2022-Jan The record is a secondary analysis (NNT/NNH) that references four Phase III trials but does not present original results from a single randomized trial. While it meets oncology, human, phase, drug, and endpoint criteria, it fails the 'original_result' criterion because it is not a primary report of a trial. Additionally, randomization is not explicitly confirmed in the abstract for the referenced trials. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. PMID 34844978 · Clin Cancer Res · 2022-Feb-15 Cannot confirm the trial phase (Phase III/IIIb or Phase II/III) from the provided metadata. The record's title, abstract, and publication type do not explicitly state the trial phase. Therefore, the eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. PMID 34644414 · Cancer · 2022-Feb-15 Eligibility cannot be confirmed because the Phase III/IIIb or Phase II/III designation for the underlying randomized trials is not explicitly established in the record. The report is a long-term follow-up of randomized trials, meeting other key criteria, but the required phase evidence is ambiguous. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Problematic Biomarker Trial Design. PMID 34289052 · J Natl Cancer Inst · 2022-Feb-07 The abstract is a commentary on biomarker trial design, not a report of specific trial results. It does not name a drug intervention or report any time-to-event efficacy endpoint (OS, PFS, etc.) for a specific study. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212). PMID 34865105 · Jpn J Clin Oncol · 2022-Feb-05 The record describes a secondary analysis of prognostic factors from the JCOG0212 trial, which is randomized and oncologic with time-to-event endpoints. However, it does not involve a drug-containing intervention (only surgical procedures are compared), and the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it does not meet all inclusion criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. PMID 35105329 · BMC Cancer · 2022-Feb-01 The trial is an oncology Phase III randomized controlled trial with a drug intervention, but the primary efficacy endpoint is overall response rate (ORR), which is a response rate, not a time-to-event endpoint. No primary or key secondary time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier analysis or hazard ratio (HR) is mentioned in the provided metadata. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. PMID 34882581 · J Clin Invest · 2022-Feb-01 The trial is an oncology randomized study in humans with a drug intervention, but it is not a Phase III trial (appears to be a pilot Phase I/II based on size and design), and it lacks a primary or key secondary time-to-event efficacy endpoint. The primary outcomes are safety and immune response, which are not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. PMID 34481017 · Int J Radiat Oncol Biol Phys · 2022-Feb-01 Record describes a long-term follow-up report of the NRG/RTOG 9408 randomized trial. It meets criteria for oncology, human, randomized, drug intervention, time-to-event endpoint, and original result reporting. Phase is not explicitly stated in the provided metadata but the trial is referenced as 'NRG/RTOG 9408', which is a known cooperative group trial typically conducted as a Phase III study; however, the prompt prohibits inferring missing phase. Therefore, phase cannot be definitively confirmed from the provided text, setting is_eligible to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. PMID 35210307 · J Immunother Cancer · 2022-Feb The study is an oncology human Phase 3b/4 trial with drug intervention and reports time-to-event efficacy results (PFS and OS). However, the primary endpoint is safety (incidence of immune-mediated AEs). While PFS and OS are reported as secondary/exploratory endpoints, the trial design (phase 3b/4) and the lack of explicit statement of randomization in the provided abstract prevent definitive eligibility. The cohort is a specific subgroup (non-clear cell RCC) of a larger trial, but it is reported as a primary result for that cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. PMID 34954100 · Contemp Clin Trials · 2022-Feb Record is a protocol for a randomized trial of screening/diagnosis in pancreatic cancer. It lacks a drug intervention and a time-to-event efficacy endpoint, and presents no results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. PMID 34911336 · Future Oncol · 2022-Feb The record is a protocol for a Phase III randomized trial of drug interventions in oncology, but it does not report any time-to-event efficacy results (e.g., KM curves, HR). Eligibility requires an original result report with a primary/key secondary time-to-event endpoint. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. PMID 34775146 · Transplant Cell Ther · 2022-Feb The record describes a Phase III randomized trial with time-to-event efficacy endpoints in human oncology. However, the drug intervention is not explicitly established in the provided abstract. The intervention appears to be transplantation procedures (umbilical cord blood or HLA-haploidentical bone marrow/peripheral blood), which are procedural, not necessarily drug-based. The eligibility criteria require a drug-containing intervention, which cannot be confirmed from the metadata. Therefore, eligibility is indeterminate. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |